🔗 Share this article

As the United States proceeds with unprecedented changes to its vaccine schedules, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccinations in the pandemic and has focused upon potential fatalities following Covid immunization in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Schedule

Agency leaders had intended to reveal sweeping changes to the pediatric immunization program earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a major change that would put the US out of step with much of the world with little proof for benefit. The announcement has been delayed until the new year.

Instead of Vinay Prasad, Dr. Høeg is set to present at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting certain childhood shot schedules in the US in order to be more like Denmark, a nation with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Questions Over Expertise

Høeg has no apparent background in drug development, approval processes or leadership, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a sizeable institution. She is not an expert in drug approvals.”

Former heads of the center would “be deeply familiar with laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that previous people who led CBER have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner stated.

“Everybody just zeroes in on the new drug program, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and other areas, and each of these have to be looked after,” Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial management aspect to the job, which manages over 5,000 staff members. “It’s a massive leadership role, if you do it right,” she said.

Response and Controversial Policies

In response to questions about Høeg’s qualifications and whether this appointment represents greater collaboration among regulatory chiefs on vaccines, a spokesperson stated that the “questions stem from incorrect presumptions”.

“Her resume aligns with the duties of her position,” the official stated, noting the period Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial one-day therapy clearance system that reportedly concerned her preceding directors. “How are these medications being chosen for this fast-track system? Who is making the decisions?” Howard said. “There’s a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration appears to be shifting towards more relaxed oversight of all drugs, except for vaccines.”

Public Past Work on Immunizations

With immunizations, Høeg has a more documented, if problematic, history, Howard have noted. She released a analysis using non-validated crowd-sourced reports to assess the frequency of myocarditis following COVID-19 vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the new federal leadership included revising guidelines for recently developed shots and discontinuing “non-essential” immunizations, she remarked after the election on a podcast. At the agency, Høeg has according to sources proposed excluding adolescent males from getting Covid vaccines.

“She’s an complete dogmatist who commences with her preconceived notions and works backwards to accommodate the data in a very disingenuous, fraudulent way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined fellow dissenters, {like|